B05 PLASMA CELL LEUKEMIA-LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM.

Autor: Hofste op Bruinink, D., Kuiper, R., van Duin, M., Cupedo, T., van der Velden, V., Hoogenboezem, R., van der Holt, B., Beverloo, B., Valent, E., Vermeulen, M., D'Agostino, M., Gay, F., Broijl, A., Avet-Loiseau, H., Munshi, N., Musto, P., Moreau, P., Zweegman, S., van de Donk, N., Sonneveld, P.

Publikováno v: HemaSphere; May2023 Supplement S2, Vol. 7, p6-6, 1p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC)

Autor: Hans Erik Johnsen, Alexander Schmitz, Julie Støve Bødker, Sonneveld, P., Hofste Op Bruinink, D., Holt, B., Velden, V. H. J., Abildgaard, N., Ahlberg, L., Andersen, N., Andreasson, B., Brandefors, L., Christiansen, H. B., Faxoe, S., Fransson, C., Friestad, M., Gregersen, H., Hammerlund, Y., Hansson, M., Haukaas, E., Hector, M., Helleberg, C., Holst, M., Jönsson, A. K., Karlsson, V., Klostergaard, A., Kjær, S., Lauri, B., Lenhoff, S., Lonn, I., Myhr, E., Pedersen, B. H., Renna, R., Sjøgren, T. V., Asta Svirskaite, Szatkowski, D. L., Vangsted, S., Waage, A., Schjesvold, F. H., U-H, Mellqvist, Helle Høholt, Louise Hvilshøj Madsen, Henning Sand Christensen, Rasmus Brøndum, Martin Bøgsted, Karen Dybkaer

Publikováno v: Aalborg University
Johnsen, H E, Schmitz, A, Bødker, J S, Sonneveld, P, Hofste op Bruinink, D, van der Holt, B, van der Velden, V H J, Abildgaard, N, Ahlberg, L, Andersen, N, Andreasson, B, Brandefors, L, Christiansen, H B, Faxoe, S, Fransson, C, Friestad, M, Gregersen, H, Hammerlund, Y, Hansson, M, Haukaas, E, Hector, M, Helleberg, C, Holst, M, Jönsson, A K, Karlsson, V, Klostergaard, A, Kjær, S, Lauri, B, Lenhoff, S, Lonn, I, Myhr, E, Pedersen, B H, Renna, R, Sjøgren, T V, Svirskaite, A, Szatkowski, D L, Vangsted, S, Waage, A, Schjesvold, F H, Mellqvist, U-H, Høholt, H, Madsen, L H, Christensen, H S, Brøndum, R F, Bøgsted, M & Dybkær, K 2018, ' Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC). ', Haematologica, vol. 103, no. S1, BA6, pp. 13 . < http://www.emn2018.com/doc/Abstract-book.pdf >

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::16f7414171447361f275e257d55088a8
https://vbn.aau.dk/en/publications/2e93ef3e-a0c1-42fd-91fc-9ee0616eb58b

Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.

Autor: Hofste op Bruinink D; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . d.hofsteopbruinink@erasmusmc.nl., Oliva S; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy., Rihova L; Department of Hematology, University Hospital Brno, Brno, Czech Republic., Schmitz A; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Gilestro M; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy., Te Marvelde J; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands., Kralova R; Department of Hematology, University Hospital Brno, Brno, Czech Republic., Høholt H; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Broijl A; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Johnsen HE; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Hajek R; Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic., Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Omedè P; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy., Van der Velden VHJ; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . v.h.j.vandervelden@erasmusmc.nl.

Publikováno v: Haematologica [Haematologica] 2020 Oct 05; Vol. 106 (5), pp. 1496-1499. Date of Electronic Publication: 2020 Oct 05.